The National Institute for Health and Care Excellence (NICE) has issued guidance recommending Santen’s Roclanda for use in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
The health technology assessment agency has specifically recommended that Roclanda be used when a fixed-dose combination (FDC) treatment has not achieved sufficient intraocular pressure (IOP) reduction, or when a FDC treatment containing beta-blockers is unsuitable…
